Paper34834201
Biomarkers for Optimization and Personalization of Anti-TNFs in Pediatric Inflammatory Bowel Disease.
Salvador-Martín S and 2 others. Pharmaceutics, 2021. Cited by 5 papers, by iCite.
Cite this record
ConductScience Library. Biomarkers for Optimization and Personalization of Anti-TNFs in Pediatric Inflammatory Bowel Disease. Papers, record 34834201. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/34834201
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Biomarkers for Optimization and Personalization of Anti-TNFs in Pediatric Inflammatory Bowel Disease.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| PI19/00792 | Instituto de Salud Carlos III | PubMed |
Source PubMed
References128
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 29027257 | Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases. | Aliment Pharmacol Ther | 2017 | https://conductscience.org/library/papers/29027257 | PubMed |
| 2 | 22643596 | Is pediatric IBD treatment different than in adults? | Minerva Gastroenterol Dietol | 2012 | https://conductscience.org/library/papers/22643596 | PubMed |
| 3 | 29618496 | Cell-centred meta-analysis reveals baseline predictors of anti-TNFα non-response in biopsy and blood of patients with IBD. | Gut | 2019 | https://conductscience.org/library/papers/29618496 | PubMed |
| 4 | 28272355 | Serum-Infliximab Trough Levels in 45 Children with Inflammatory Bowel Disease on Maintenance Treatment. | Int J Mol Sci | 2017 | https://conductscience.org/library/papers/28272355 | PubMed |
| 5 | 31126015 | A Review on the Use of Anti-TNF in Children and Adolescents with Inflammatory Bowel Disease. | Int J Mol Sci | 2019 | https://conductscience.org/library/papers/31126015 | PubMed |
| 6 | 29957083 | How to predict response to anti-tumour necrosis factor agents in inflammatory bowel disease. | Expert Rev Gastroenterol Hepatol | 2018 | https://conductscience.org/library/papers/29957083 | PubMed |
| 7 | 27636407 | Biological Therapy in Pediatric Inflammatory Bowel Disease: A Systematic Review. | J Clin Gastroenterol | 2017 | https://conductscience.org/library/papers/27636407 | PubMed |
| 8 | 24162032 | Increased effectiveness of early therapy with anti-tumor necrosis factor-α vs an immunomodulator in children with Crohn's disease. | Gastroenterology | 2014 | https://conductscience.org/library/papers/24162032 | PubMed |
| 9 | 29487490 | Pediatric Crohn's Disease. | Clin Colon Rectal Surg | 2018 | https://conductscience.org/library/papers/29487490 | PubMed |
| 10 | 29202588 | Therapeutic drug monitoring of anti-TNF therapy in children with inflammatory bowel disease. | Expert Opin Drug Saf | 2018 | https://conductscience.org/library/papers/29202588 | PubMed |
| 11 | 32813123 | Infliximab in young paediatric IBD patients: it is all about the dosing. | Eur J Pediatr | 2020 | https://conductscience.org/library/papers/32813123 | PubMed |
| 12 | 31777929 | Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice. | J Crohns Colitis | 2020 | https://conductscience.org/library/papers/31777929 | PubMed |
| 13 | 30211845 | Causes of Treatment Failure in Children With Inflammatory Bowel Disease Treated With Infliximab: A Pharmacokinetic Study. | J Pediatr Gastroenterol Nutr | 2019 | https://conductscience.org/library/papers/30211845 | PubMed |
| 14 | 33026087 | The Medical Management of Paediatric Crohn's Disease: an ECCO-ESPGHAN Guideline Update. | J Crohns Colitis | 2021 | https://conductscience.org/library/papers/33026087 | PubMed |
| 15 | 25784738 | How effective is the use of long-term anti-TNF for paediatric IBD? Clues from real-life surveillance cohorts. | Arch Dis Child | 2015 | https://conductscience.org/library/papers/25784738 | PubMed |
| 16 | 26308438 | Restoration of Foxp3+ Regulatory T-cell Subsets and Foxp3- Type 1 Regulatory-like T Cells in Inflammatory Bowel Diseases During Anti-tumor Necrosis Factor Therapy. | Inflamm Bowel Dis | 2015 | https://conductscience.org/library/papers/26308438 | PubMed |
| 17 | 31247074 | Proactive Infliximab Drug Monitoring Is Superior to Conventional Management in Inflammatory Bowel Disease. | Inflamm Bowel Dis | 2020 | https://conductscience.org/library/papers/31247074 | PubMed |
| 18 | 27609485 | Clinical Use of Measuring Trough Levels and Antibodies against Infliximab in Patients with Pediatric Inflammatory Bowel Disease. | Gut Liver | 2017 | https://conductscience.org/library/papers/27609485 | PubMed |
| 19 | 32773718 | Genetic Predictors of Long-term Response to Antitumor Necrosis Factor Agents in Pediatric Inflammatory Bowel Disease. | J Pediatr Gastroenterol Nutr | 2020 | https://conductscience.org/library/papers/32773718 | PubMed |
| 20 | 24776844 | Associations between functional polymorphisms in the NFκB signaling pathway and response to anti-TNF treatment in Danish patients with inflammatory bowel disease. | Pharmacogenomics J | 2014 | https://conductscience.org/library/papers/24776844 | PubMed |
Cited by4
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 5 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 38507036 | The Effect of Polymorphisms and Other Biomarkers on Infliximab Exposure in Paediatric Inflammatory Bowel Disease: Development of a Population Pharmacokinetic Model. | Paediatr Drugs | 2024 | https://conductscience.org/library/papers/38507036 | PubMed |
| 37808875 | Predicting pediatric Crohn's disease based on six mRNA-constructed risk signature using comprehensive bioinformatic approaches. | Open Life Sci | 2023 | https://conductscience.org/library/papers/37808875 | PubMed |
| 36675312 | Association between HLA DNA Variants and Long-Term Response to Anti-TNF Drugs in a Spanish Pediatric Inflammatory Bowel Disease Cohort. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/36675312 | PubMed |
| 35908771 | JNK pathway-associated phosphatase illustrates low expression and negative correlations with inflammation, disease activity, and T-helper 17 cells in inflammatory bowel disease children. | J Clin Lab Anal | 2022 | https://conductscience.org/library/papers/35908771 | PubMed |
Genes101
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/34834201
GET https://conductscience.org/api/papers/v1/34834201/references?page=2